You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(05.17)︱同程藝龍一季度經調整純利大增279.5%;康哲藥業收購一家醫療美容聚焦超聲技術平台公司
格隆匯 05-17 23:31

【分拆上市】

中集集團(02039.HK):董事會同意中集安瑞環科擬於深交所發行A股並上市

【財務數據】

同程藝龍(00780.HK)一季度經調整純利大增279.5% 總交易額升83%至333億元

億勝生物科技(01061.HK)前4個月收益約4.38億港元 同比增長242.2%

【業績預吿】

震雄集團(00057.HK)預計年度純利增長逾110%

創升控股(02680.HK)年度純利預增不少於40%

FAIRWOOD HOLD(00052.HK)年度預盈1.5億港元

KFM金德(03816.HK)預期2021財年純利約1900萬港元

【運營數據】

齊屹科技(01739.HK):一季度SaaS及延伸服務業務收入同比增加75%

【增減持】

時代鄰里(09928.HK)獲控股股東卓源增持90萬股

【股權變更】

紅星美凱龍(01528.HK)控股股東擬將不超1800萬股公司股份轉讓給其一致行動人西藏奕盈

【併購出售】

康哲藥業(00867.HK)擬收購一家醫療美容聚焦超聲技術平台公司

寶業集團(02355.HK)擬2.03億元收購武漢裕築房地產開發剩餘51%股權

新豐泰集團(01771.HK)擬1.5億元出售西安秦睿置業25%股權

上海實業環境(00807.HK)附屬擬收購河南聞諾80%股權 上實環境武漢註冊股本增至4.66億元

金茂源環保(06805.HK)競得四川青神縣一地塊使用權

【投資運營】

德琪醫藥-B(06996.HK)與Calithera達成CD73抑制劑CB-708 (ATG-037)開發和商業化的全球獨家授權協議

雲頂新耀-B(01952.HK):國家藥品監督管理局受理創新藥戈沙妥組單抗治療轉移性三陰性乳腺癌生物製品上市許可申請

中國交通建設(01800.HK)成立項目公司以共同投資洪湖市施墩河湖中心河片區綜合治理PPP項目

阜博集團(03738.HK)擬為新傳在線提供版權保護和內容管理變現服務

旅橙文化(08627.HK)擬成立業務公司 從事媒體制作業務

榮昌生物-B(09995.HK):H股全流通獲聯交所授出上市批准

華記環球集團(02296.HK)旗下華記環球設計年初至今已落實超30個設計項目

康希諾生物-B(06185.HK):上藥康希諾註冊資本將增加至12.05億元

億都(國際控股)(00259.HK):南通江海及蘇州金龍共同開發的首台鋰離子超級電容器純電動客車已成功推出

中州證券(01375.HK):獲得政府補助合計1224.21萬元

【回購註銷】

日清食品(01475.HK)5月17日耗資898萬港元回購147萬股

海爾智家(06690.HK)5月17日回購118.36萬股H股及5萬股A股

中國旺旺(00151.HK)5月17日耗資162.71萬港元回購28.2萬股

【股權激勵】

怡園酒業(08146.HK)授出1000萬份購股權

藍港互動(08267.HK)授出合共364.5萬份購股權

都市麗人(02298.HK):受託人就股份獎勵計劃購買50萬股

美高梅中國(02282.HK)授出29萬份購股權

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account